Lixte Biotechnology Holdings, Inc.
LIXT
$4.87
$0.9022.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6.36% | -6.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.22% | -37.61% | |||
| Operating Income | -15.22% | 37.61% | |||
| Income Before Tax | -14.88% | 37.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -14.88% | 37.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.88% | 37.35% | |||
| EBIT | -15.22% | 37.61% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -4.55% | 37.36% | |||
| Normalized Basic EPS | -4.55% | 37.37% | |||
| EPS Diluted | -4.55% | 37.36% | |||
| Normalized Diluted EPS | -4.55% | 37.37% | |||
| Average Basic Shares Outstanding | 9.88% | 0.00% | |||
| Average Diluted Shares Outstanding | 9.88% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||